Catalent (CTLT) Stock Price, News & Analysis

-0.11 (-0.20%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.03 million shs
Average Volume
2.55 million shs
Market Capitalization
$10.12 billion
P/E Ratio
Dividend Yield
Price Target

Catalent MarketRank™ Stock Analysis

Analyst Rating
2.15 Rating Score
6.2% Downside
$52.46 Price Target
Short Interest
4.15% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.03mentions of Catalent in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$21,749 Sold Last Quarter
Proj. Earnings Growth
From $0.28 to $1.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.18 out of 5 stars

Medical Sector

311th out of 909 stocks

Pharmaceutical Preparations Industry

139th out of 423 stocks

CTLT stock logo

About Catalent Stock (NYSE:CTLT)

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

CTLT Stock Price History

CTLT Stock News Headlines

Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Midday movers: Tesla, Coinbase rise; Uber falls
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
CTLT Apr 2024 17.500 call
CTLT Apr 2024 30.000 call
Catalent slashes 90 Bay Area jobs
In-Depth Examination Of 5 Analyst Recommendations For Catalent
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$4.28 billion
Cash Flow
$3.23 per share
Book Value
$25.58 per share


Free Float
Market Cap
$10.10 billion
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

CTLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price target for 2024?

13 Wall Street analysts have issued twelve-month target prices for Catalent's stock. Their CTLT share price targets range from $42.00 to $63.50. On average, they predict the company's stock price to reach $52.46 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2024?

Catalent's stock was trading at $44.93 at the beginning of 2024. Since then, CTLT stock has increased by 24.5% and is now trading at $55.95.
View the best growth stocks for 2024 here

Are investors shorting Catalent?

Catalent saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 7,850,000 shares, an increase of 8.4% from the February 29th total of 7,240,000 shares. Based on an average daily trading volume, of 2,700,000 shares, the short-interest ratio is presently 2.9 days.
View Catalent's Short Interest

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our CTLT earnings forecast

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Friday, February, 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.22. The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative trailing twelve-month return on equity of 2.43%. The firm's quarterly revenue was down 10.2% compared to the same quarter last year. During the same period last year, the business earned $0.62 earnings per share.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Who are Catalent's major shareholders?

Catalent's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.23%), Amalgamated Bank (0.03%), Mountain Pacific Investment Advisers Inc. ID (0.02%), IFM Investors Pty Ltd (0.02%) and Czech National Bank (0.02%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano and Thomas W Hawkeswood.
View institutional ownership trends

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CTLT) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners